SCHEMBL19989322

SCHEMBL19989322

Cc1cc(S(=O)(=O)N2CCC[C@H]2C=O)ccc1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
KMT2A Q03164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ABL1 P00519 1/20 0.43
RIN1 Q13671 1/20 0.43
TRPA1 O75762 1/20 0.42
AKR1C3 P42330 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
PKM P14618 1/20 0.40
CASP3 P42574 5/20 0.39
CASP7 P55210 4/20 0.39
HTR7 P34969 2/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19989324 1.00 ALDH1A1 (0.48) ALDH1A1MEN1LMNAKMT2AL3MBTL1
SCHEMBL29859256 0.83 AKR1C3 (0.57) ALDH1A1MEN1LMNAKMT2AL3MBTL1
SCHEMBL19989320 0.81 LOX (0.51) ALDH1A1MEN1LMNAKMT2AL3MBTL1
SCHEMBL19989318 0.81 LOX (0.51) ALDH1A1MEN1LMNAKMT2AL3MBTL1
SCHEMBL19989210 0.81 LOX (0.51) ALDH1A1MEN1LMNAKMT2AL3MBTL1
SCHEMBL6879707 0.81 L3MBTL1 (0.51) ALDH1A1MEN1KMT2AL3MBTL1PKM
SCHEMBL9042461 0.81 L3MBTL1 (0.51) ALDH1A1MEN1KMT2AL3MBTL1PKM
SCHEMBL10904190 0.81 L3MBTL1 (0.51) ALDH1A1MEN1KMT2AL3MBTL1PKM
SCHEMBL28831491 0.80 L3MBTL1 (0.51) ALDH1A1MEN1LMNAKMT2AL3MBTL1
SCHEMBL19989286 0.78 ALDH1A1 (0.46) ALDH1A1MEN1LMNAKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109715608-B Indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-08-05 CN disclosed
EP-3515894-B1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2021-04-07 EP disclosed
EP-3515894-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES Novartis AG (CH) 2019-07-31 EP disclosed
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries NOVARTIS AG (CH) 2018-10-30 US disclosed
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2018-03-29 US disclosed
WO-2018055550-A1 INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES NOVARTIS AG (CH) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112907-B2 Substituted indazoles for treating tendon and/or ligament injuries SLC10A2, MMP1, TNNI3 ALDH1A1 442/4885MEN1 2014/4885LMNA 678/4885
US-20180086716-A1 Indazole Compounds for Use in Tendon and/or Ligament Injuries MMP1, SLC10A2, TNNI3 ALDH1A1 414/4885MEN1 2007/4885LMNA 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.